breast cancer – Medxy AI

Ocular Metastasis Over Four Decades: Clinical Patterns, Survival, and Therapeutic Outcomes in 569 Patients

By MedXY 10/20/2026

A 40-year retrospective study of 569 patients with ocular metastases reveals persistently poor survival, dominated by breast and lung primaries, with vision often preserved through treatment despite no significant survival improvements over time.

General Surgery news Oncology

De-escalating Axillary Surgery in Early Breast Cancer: Implementing SOUND and INSEMA Trials in Clinical Practice

By MedXY 10/17/2026

Omission of sentinel lymph node biopsy (SLNB) in select postmenopausal patients with early HR+/HER2- breast cancer and negative axillary ultrasound is feasible and safe, reducing surgical morbidity without compromising short-term outcomes.

news Oncology Ophthalmology

Corneal Epithelial Changes Induced by CDK4/6 Inhibitors in HR+ Breast Cancer: Clinical Insights and Implications

By MedXY 10/14/2026

CDK4/6 inhibitor therapy in hormone receptor-positive breast cancer is linked to increased corneal epithelial alterations, including punctate epitheliopathy and vortex keratopathy, independent of aromatase inhibitor effects or tear film dysfunction.

General Surgery news Oncology

Evolving Surgical Patterns and Outcomes in Young Women with Breast Cancer: Insights from a Decade of National Data

By MedXY 10/08/2026

This large-scale study reveals that adolescent and young adult women with breast cancer predominantly undergo mastectomy and experience comparable perioperative outcomes to older women, despite a higher metastatic burden.

General Surgery news Oncology

Reevaluating Sentinel Lymph Node Biopsy in Older Women with cT2N0 HR+/HER2- Breast Cancer: Limited Impact on Treatment Decisions

By MedXY 10/04/2026

In women aged 65 and older with cT2N0 hormone receptor-positive, HER2-negative breast cancer, sentinel lymph node biopsy rarely alters adjuvant therapy plans, supporting a more individualized approach to axillary staging in this population.

Cardiology news Oncology

Breast Cancer-Derived ADAM10: A Novel Mediator of Atrial Fibrillation Through Atrial Fibrosis

By MedXY 09/20/2026

Breast cancer independently increases atrial fibrillation risk via tumour-secreted ADAM10, which induces atrial fibrosis through the Ephrin B2 signaling pathway, offering a potential new therapeutic target.

Cardiology news Oncology

Proteomic and Metabolomic Insights into Cardiac Remodeling in Breast Cancer Patients Undergoing Cardiotoxic Therapy

By MedXY 09/19/2026

This study identifies novel proteomic and metabolomic biomarkers linked to cardiac dysfunction and remodeling in breast cancer patients treated with cardiotoxic therapies, revealing potential pathways for early detection and intervention.

news Oncology Radiology

Enhancing Intraoperative Margin Assessment in Early-Stage Breast Cancer with Specimen PET-CT Imaging: Insights from the BrIMA Trial

By MedXY 07/15/2026

The BrIMA trial demonstrates that specimen PET-CT imaging significantly improves intraoperative detection of positive margins during breast-conserving surgery for early-stage breast cancer, reducing re-excision rates and enhancing surgical outcomes.

Cardiology Clinical Updates news Radiology

Cardiac Risk After Heart-Sparing Breast Radiotherapy: Emphasis on Left Anterior Descending Artery Dose Metrics

By MedXY 07/02/2026

Emerging evidence indicates that radiation dose to the left anterior descending coronary artery better predicts cardiac events than whole-heart dose in breast radiotherapy, emphasizing the importance of LAD-based planning to reduce long-term cardiac risks.

Diabetes & Endocrinology news Oncology

GLP-1 Receptor Agonists May Outperform Bariatric Surgery for Breast Cancer Outcomes in Obese Postmenopausal Women

By MedXY 06/18/2026

In a large TriNetX study, GLP-1 receptor agonists were associated with better overall survival and lower locoregional recurrence than bariatric surgery alone in obese postmenopausal women with stage 0-III breast cancer.

Hematology-Oncology news OB/GYN & Women’s Health

GLP-1 Receptor Agonists May Outperform Bariatric Surgery in Obese Postmenopausal Breast Cancer Patients, Study Suggests

By MedXY 06/18/2026

A large real-world study found GLP-1 receptor agonists were associated with better survival and lower locoregional recurrence than bariatric surgery in postmenopausal women with obesity and breast cancer.

news OB/GYN & Women’s Health Oncology

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial

By MedXY 06/10/2026

Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in advanced hormone receptor-positive, ERBB2-negative breast cancer, with manageable safety and no clear quality-of-life loss.

news Oncology Public Health

Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM Study

By MedXY 06/09/2026

This WISDOM Study analysis found that most women with breast cancer pathogenic variants would not have been flagged for high-risk screening by clinical or polygenic risk models alone, supporting population-based genetic testing.

news OB/GYN & Women’s Health Oncology

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial

By MedXY 06/03/2026

Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in hormone receptor-positive, ERBB2-negative advanced breast cancer with manageable toxicity and preserved quality of life.

Clinical Updates news Oncology

Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial and Comparative Synthesis

By MedXY 05/23/2026

This review synthesizes the BRIGHT-2 trial findings and meta-analytical data, confirming that bireociclib plus fulvestrant significantly improves progression-free survival in HR+/HER2- advanced breast cancer.

General Surgery news Oncology

Survival Outcomes After Neoadjuvant Chemotherapy in Node-Positive Hormone Receptor-Positive Breast Cancer”,

By MedXY 05/18/2026

A national database study found that neoadjuvant chemotherapy was linked to worse overall survival than upfront surgery in node-positive hormone receptor-positive, HER2-negative breast cancer, except in patients who achieved nodal complete response.

news Oncology Public Health

Quality of Breast Cancer Care and Patient Survival Show No Link to Hospital Safety-Net Burden

By MedXY 05/01/2026

A major study reveals that safety-net hospitals—serving vulnerable Medicaid and uninsured patients—deliver breast cancer care and survival outcomes on par with other hospitals, challenging assumptions about quality disparities in resource-constrained settings.

Clinical Updates news OB/GYN & Women's Health Oncology

Tamoxifen and Uterine Disease Risk in Young Breast Cancer Survivors: Evidence from a Target Trial Emulation Study

By MedXY 03/13/2026

A large-scale cohort study of premenopausal women demonstrates that adjuvant tamoxifen significantly increases the risk of endometrial cancer, hyperplasia, and polyps, with risk correlating to treatment duration.

news OB/GYN & Women's Health Oncology

Rethinking Frontline Standards: SONIA Trial Finds No Survival Benefit for First-Line CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer

By MedXY 03/12/2026

The Phase 3 SONIA trial demonstrates that delaying CDK4/6 inhibitors to the second-line setting for advanced breast cancer yields comparable overall survival to first-line use, while significantly reducing treatment-related toxicities and healthcare costs.

Cardiology news Oncology

The BMPR2 Nexus: How Breast Cancer Acts as a Second Hit for Pulmonary Hypertension

By MedXY 03/01/2026

Emerging evidence identifies a bidirectional link between breast cancer and pulmonary arterial hypertension (PAH) driven by BMPR2 signaling and IL-1β-mediated inflammation. This study suggests breast cancer may serve as a critical second hit, unmasking latent vascular susceptibility in at-risk populations.